12:00 AM
 | 
Oct 22, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

EB-1020: Phase I data

A Phase I trial in about 50 healthy volunteers showed that single and multiple ascending-doses of EB-1020 were well tolerated. Neurovance plans to start...

Read the full 98 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >